CHICAGO — Anti-VEGF monotherapy for treatment of retinopathy of prematurity was more expensive than anti-VEGF therapy combined with panretinal photocoagulation, according to a speaker here, but both modalities exhibited positive outcomes at the final examination.
“This study demonstrates the direct financial impact of ROP screening and treatment in infants. ... Monotherapy has marginal increased costs with escalating number of visits compared with treatment with laser,” Swati Agarwal-Sinha, MD, said at the American Society of Retina Specialists annual meeting.
Researchers
Uncategorized